PfVP1, a battery of the malaria parasite, is critical for ring stage development
PfVP1 是疟疾寄生虫的一组,对于环期发育至关重要
基本信息
- 批准号:10116730
- 负责人:
- 金额:$ 22.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-11-10 至 2022-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntimalarialsArchaeaBacteriaBiochemicalBioenergeticsBiologicalBiologyBloodBudgetsCRISPR/Cas technologyCell membraneCellsComplementConsumptionContractsDNA biosynthesisDataDevelopmentDiphosphatesDrug resistanceEnergy SupplyEnergy-Generating ResourcesErythrocytesFutureGeneticGlucoseGlycolysisHumanHydrolysisKnock-outMalariaMammalian CellMeasuresMediatingMembraneMetabolicMolecular TargetMutagenesisMutateNutrientOrganismOxidative PhosphorylationParasitesPhysiologicalPlantsPlasmodium falciparumProcessProteinsProton PumpProtonsRNAReactionRegulatory ElementResistanceResistance developmentRiskRoleRouteRunningSaccharomyces cerevisiaeTestingTimeVacuoleVesicleWaste ProductsYeastsasexualbasecostdrug developmentfungusgenomic locusglobal healthinsightknock-downmetabolic ratenutritionpyrophosphatasesodium ionuptake
项目摘要
Project Summary
Malaria remains a major global health concern and the control progress has run into a serious
bottleneck in recent years. Each year, more than 3 billion people are living at risk of contracting
malaria, 200 million people are infected and half a million people die from malaria. As malaria
parasites rapidly develop resistance to available antimalarial drugs, a better understanding of
fundamental biology is urgently needed. In the asexual blood stages, malaria parasites mainly
reply on glycolysis for energy since the parasite's mitochondrion does not perform oxidative
phosphorylation to produce ATP. They also contain membrane bound proton pumping
pyrophosphatases (mPPases), which use pyrophosphate, the by-product of over 200 cellular
reactions, as the energy source to pump protons across a membrane. We have previously
knocked out PfVP2 (PF3D7_1235200) whereas PfVP1 (PF3D7_1456800) has been predicted
to be essential. Using a CRISPR/Cas9 mediated genetic tagging/conditional knockdown, we
have found that PfVP1 is localized to the parasite plasma membrane and is essential for ring
stage development. In this application, we hypothesize that PfVP1 uses pyrophosphate as an
alternative energy source to sustain a proton electrochemical gradient in the ring stage
development of Plasmodium falciparum. We will test this hypothesis in the following aims.
Aim 1, Assess the activity of PfVP1 as an integral membrane proton-pumping pyrophosphatase.
Aim 2, Define the function of PfVP1 in ring stage parasites. Together, this proposal will uncover
important insights of ring stage development and bioenergetics, critical yet understudied
aspects of parasite biology. If successful, the studies proposed here will provide direct evidence
that an alternative energy source is critical for early stage development of a malaria parasite in
RBCs. Finding a critical molecular target at the ring stage will also facilitate target-based drug
development in future to better inhibit metabolically less active parasite forms that are often
resistant to current antimalarials.
项目摘要
疟疾仍然是一个主要的全球健康问题,控制进展遇到了严重的问题,
近年来的瓶颈。每年有超过30亿人生活在感染的风险中,
有2亿人感染疟疾,50万人死于疟疾。疟疾
寄生虫迅速对现有的抗疟药物产生耐药性,
基础生物学是迫切需要的。在无性血液阶段,疟原虫主要
回答糖酵解的能量,因为寄生虫的寄生虫不进行氧化
磷酸化产生ATP。它们还包含膜结合质子泵
焦磷酸酶(mPPases),它使用焦磷酸盐,超过200个细胞的副产物,
反应,作为能量源泵质子穿过膜。我们先前已经
敲除PfVP 2(PF3D7_1235200),而预测PfVP 1(PF3D7_1456800)
是必不可少的。使用CRISPR/Cas9介导的遗传标记/条件性敲低,
已经发现PfVP 1定位于寄生虫质膜,并且是环
阶段发展。在本应用中,我们假设PfVP 1使用焦磷酸盐作为
替代能源以维持环级中的质子电化学梯度
恶性疟原虫的发展。我们将在以下目标中检验这一假设。
目的1、研究PfVP 1作为膜质子泵焦磷酸酶的活性。
目的2、明确PfVP 1在环期寄生虫中的功能。这项提案将揭示
环阶段发展和生物能量学的重要见解,关键但未充分研究
寄生虫生物学的各个方面。如果成功,这里提出的研究将提供直接证据,
替代能源对于疟疾寄生虫的早期发展至关重要,
红细胞。在环阶段找到关键的分子靶点也将有助于靶向药物的开发。
未来的发展,以更好地抑制代谢活性较低的寄生虫形式,
对目前的抗疟药有抗药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hangjun Ke其他文献
Hangjun Ke的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hangjun Ke', 18)}}的其他基金
PfVP1, a battery of the malaria parasite, is critical for ring stage development
PfVP1 是疟疾寄生虫的一组,对于环期发育至关重要
- 批准号:
10300573 - 财政年份:2020
- 资助金额:
$ 22.56万 - 项目类别:
Nonconventional mitochondrial ribosomes of malaria parasites
疟疾寄生虫的非常规线粒体核糖体
- 批准号:
9537410 - 财政年份:2017
- 资助金额:
$ 22.56万 - 项目类别:
Nonconventional mitochondrial ribosomes of malaria parasites
疟疾寄生虫的非常规线粒体核糖体
- 批准号:
9222483 - 财政年份:2017
- 资助金额:
$ 22.56万 - 项目类别:
相似海外基金
Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
- 批准号:
MR/X030202/1 - 财政年份:2023
- 资助金额:
$ 22.56万 - 项目类别:
Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
- 批准号:
10742205 - 财政年份:2023
- 资助金额:
$ 22.56万 - 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
- 批准号:
10635649 - 财政年份:2023
- 资助金额:
$ 22.56万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10534667 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
- 批准号:
468862 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Operating Grants
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
- 批准号:
2749037 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Studentship
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10368441 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10663334 - 财政年份:2022
- 资助金额:
$ 22.56万 - 项目类别: